Table 6 Subgroup analysis of ADSCs transplantation on neurological improvement after stroke
Variable | Effect size | ||
|---|---|---|---|
SMD (95% CI) | p value | Heterogeneity (p value) | |
Species | |||
 Mice | NA | NA | NA |
 Rat | 2.16 (1.38 to 2.94) | < 0.0001 | 89.0% (< 0.0001) |
Duration of occlusion | |||
 ≤ 60 min | 4.32 (3.15 to 5.49) | < 0.0001 | 43.6% (0.183) |
 > 60 min | 1.56 (0.98 to 2.13) | < 0.0001 | 79.3% (< 0.0001) |
Stroke model | |||
 MCAO | 2.51 (1.46 to 3.56) | < 0.0001 | 90.2% (< 0.0001) |
 Carotid clamp | 0.98 (0.60 to 1.36) | < 0.0001 | 0.0% (0.683) |
Type of administration | |||
 Intracranial | 2.66 (0.42 to 4.90) | 0.020 | 93.8% (< 0.0001) |
 Intravenous | 2.35 (0.98 to 3.71) | < 0.001 | 89.1% (< 0.0001) |
 Intra-artery | 1.14 (0.63 to 1.65) | < 0.0001 | 50.8% (0.131) |
Type of graft | |||
 Autograft | 1.40 (0.66 to 2.14) | < 0.0001 | 22.5% (0.256) |
 Allograft | 1.82 (0.86 to 2.77) | < 0.0001 | 86.0% (< 0.0001) |
 Xenograft | 2.83 (0.81 to 4.84) | 0.006 | 94.2% (< 0.0001) |
Number of transplanted cells | |||
 1 × 104 to 5 × 105 | 1.19 (0.92 to 1.45) | < 0.0001 | 85.4% (< 0.0001) |
 1 × 106 to 1.2 × 106 | 2.99 (2.05 to 3.92) | < 0.0001 | 47.1% (0.169) |
 2 × 106 | 2.31 (1.64 to 2.98) | < 0.0001 | 95.4% (< 0.0001) |
Interval time from stroke to treatment | |||
 0 to 3 h | 2.07 (1.29 to 2.85) | < 0.0001 | 63.3% (0.028) |
 24 h | 2.05 (0.99 to 3.10) | < 0.0001 | 92.0% (< 0.0001) |
 More than 7 days | No data | No data | No data |
Follow up duration | |||
 < 28 days | 1.74 (0.68 to 2.79) | 0.001 | 87.8% (< 0.0001) |
 ≥ 28 days | 2.28 (1.20 to 3.36) | < 0.0001 | 89.1% (< 0.0001) |